Nearly 12,000 children under five in Gaza face acute malnutrition, WHO reports
"In July, nearly 12,000 children under five years were identified as having acute malnutrition in Gaza, the highest monthly figure ever recorded," Tedros Adhanom Ghebreyesus said at his organisation's headquarters in Geneva.
At least 99 people have died, including 64 adults and 35 children, of whom 29 were younger than five, from the start of this year to July 29.
Between June and July, the number of admissions for malnutrition almost doubled – from 6,344 to 11,877 – according to the latest UNICEF figures available.
Some 2,500 of those children are suffering from severe malnutrition.
Tedros called for greater volumes of sustained aid via all possible routes.
The WHO said it was supporting Gaza's four malnutrition centres, but that supplies of baby formula and nutritional foods were very low.
"The overall volume of nutrition supplies remains completely insufficient to prevent further deterioration. The market needs to be flooded. There needs to be dietary diversity," said Rik Peeperkorn, WHO's representative for the occupied Palestinian Territory, via video link.
A global hunger monitor has said a famine scenario is unfolding in the Gaza Strip, with starvation spreading, children dying of hunger-related causes and humanitarian access to the embattled enclave severely restricted.
The United Nations Office for the Coordination of Humanitarian Affairs (OCHA) said food consumption across Gaza had declined to its lowest level since the onset of the war.
Eighty-one percent of households in the tiny, crowded coastal territory of 2.2 million people reported poor food consumption, up from 33 percent in April.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AFP
2 hours ago
- AFP
Social media posts misleadingly describe lenacapavir as a vaccine
'UPDATE: WHO has approved Kenya to roll out the Lenacapavir injectable HIV vaccine. You will rush for this more than the one for Corona,' reads an English and Swahili Facebook post published on July 15, 2025. Image Screenshot of the misleading Facebook post, taken on August 1, 2025 Similar claims were published here and here on Facebook. HIV breakthrough HIV is a virus that attacks the body's immune system by targeting white blood cells. These cells are essential in helping the body fight against infections and diseases (archived here). It is transmitted through contact with bodily fluids such as blood and semen from an infected person, and if left untreated, HIV can advance to AIDS (Acquired Immunodeficiency Syndrome), the most severe stage of infection. At the end of 2024, the World Health Organization (WHO) estimated that 40.8 million people were living with HIV globally, with 65 percent of them in the WHO African Region. Administered as a twice-yearly injection and developed by Gilead Sciences, LEN represents a major advancement in the fight against HIV and was approved by the US Food and Drug Administration on July 1, 2025 (archived here and here). Image Drugmaker Gilead manufactures lenacapavir (GETTY IMAGES NORTH AMERICA / JUSTIN SULLIVAN) During the 13th International AIDS Society Conference (IAS 2025) on HIV Science in Kigali, Rwanda, this July, the WHO also endorsed the drug, issuing guidelines recommending it as an additional pre-exposure prophylaxis (PrEP) option for people at high risk of HIV infection (archived here). PrEP is medication taken by individuals who do not have HIV but are at risk of contracting it. In case of infection, these treatments help the body stop the virus from replicating (archived here). Kenya was selected as one of the nine early adopter countries for the rollout of LEN, scheduled for January 2026. According to the country's health ministry, each dose is expected to cost 6,000 Kenyan shillings (about $46) (archived here and here). However, social media posts describing LEN as a vaccine are misleading. Not a vaccine According to its manufacturer, Gilead Sciences, LEN, marketed under the brand names Sunlenca and Yeztugo, is approved for two uses: as a treatment for adults who are resistant to other HIV treatments -- combined with other ARVs -- and as a PrEP option to reduce the risk of sexually acquired HIV (archived here and here). ARVs are used to treat HIV. They do not cure the virus but are a lifelong treatment that works by suppressing the infection to prevent it from progressing to AIDS (archived here). Kenya's director general for health, Dr. Patrick Amoth, told AFP Fact Check: 'Lenacapavir is not a vaccine. It is an antiretroviral medicine that prevents HIV infection.' This is different from how a vaccine affects the body. Vaccines train the immune system to recognise and fight specific pathogens before a person is infected. They do so by imitating an infection to trigger the body's natural defences. This helps the body identify the pathogen so it can respond quickly if exposed to it in the future, preventing disease (archived here). In contrast, ARVs like LEN are used to treat those already living with HIV or to prevent infection in the case of PrEP. These drugs work by blocking the virus at different stages of its lifecycle, and when taken consistently, they help control the infection and prevent transmission to others (archived here). 'Vaccines work by stimulating the body to produce antibodies against a disease,' Amoth said. 'Lenacapavir is a capsid inhibitor, blocking HIV from replicating by interfering with viral assembly and release, hence allowing the body to prevent new infections.' The capsid is the protein shell of an infectious virus that encases its genetic material. Capsids help viruses such as HIV survive. Drugs that are capsid inhibitors, like LEN, disrupt viral replication and protect the host from infection (archived here and here). Dr Andrew Mulwa, head of Kenya's National AIDS & STI Control Program (NASCOP), reiterated that LEN is not a vaccine. 'Lenacapavir, just like Cabotegravir, is an antiretroviral drug,' Mulwa told AFP Fact Check. Cabotegravir, marketed as Apretude and Cabenuva, was the first long-acting injectable PrEP that was approved by the FDA in 2021. It is administered as two initial injections four weeks apart, followed by an injection every two months (archived here). During his opening remarks at the IAS 2025 conference, WHO Director-General Dr Tedros Adhanom Ghebreyesus said: 'While an HIV vaccine remains elusive, lenacapavir is the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk' (archived here). AFP Fact Check has debunked other HIV-related claims here.
Euronews
13 hours ago
- Euronews
What we know about the West Nile virus spreading in Europe
Ten people have died of West Nile virus in Italy this year, with cases of the mosquito-borne illness also reported in other parts of Europe. As summer heats up, health authorities have warned Europeans to take steps to prevent themselves from being infected with the West Nile virus and other mosquito-borne illnesses, including chikungunya, dengue, and Zika. But what exactly do we know about the West Nile virus? Where does the virus come from? Spread through the bite of infected mosquitoes, the West Nile virus infects both humans and birds. But in very rare cases, it can also be transmitted through blood transfusions, organ transplants, and breast milk. Its name dates back to 1937, when it first appeared in the West Nile region of Uganda. It was introduced to the United States in 1999, and has since become widely established across the globe, according to the World Health Organization (WHO). Today, it is commonly found in Africa, Europe, the Middle East, North America, and west Asia. West Nile virus often spreads from mid summer to early autumn in regions with warmer weather. Research has shown that climate change is accelerating the spread of mosquito-borne viruses in Europe. In addition to Italy, infections have been reported in Bulgaria, France, Greece, and Romania this year, according to the European Centre for Disease Prevention and Control (ECDC). The virus was also detected in mosquitoes in the United Kingdom for the first time earlier this year. What are the symptoms of West Nile virus? Most people who are infected with West Nile virus will have no symptoms. But about one in five people will develop West Nile fiver, which causes body aches, headaches, vomiting, fatigue, rashes, and swollen lymph glands. Around one in 150 infected people develop a more serious form of the disease that can cause neurological complications, coma, tremours, convulsions, muscle weakness, and paralysis. Serious illness can occur in people of any age, however people over the age of 50 and some immunocompromised persons (for example, transplant patients) are at the highest risk for getting severely ill when infected with WNV. People with compromised immune systems and those over the age of 50 are at higher risk of these complications. In rare cases, West Nile virus can cause fatal neurological disease. What is recovery like? There is no vaccine or specific treatment for people with Nest Nile virus. Rest, fluids, and pain medications can help alleviate some symptoms. Patients with a neuro-invasive illness are usually hospitalised and given intravenous fluids and respiratory support while they recover, the WHO said. Once infected, people are believed to be protected against the virus for life. Beyond treatment, public health authorities are focused on preventing people from infection in the first place. These efforts rely heavily on local mosquito control programmes and personal protection. Authorities recommend that people use insect spray and wear long-sleeved shirts and trousers to keep themselves from being bitten by mosquitoes.
France 24
a day ago
- France 24
WHO says nearly 100,000 struck with cholera in Sudan
Since April 2023, Sudan has been torn apart by a power struggle between army chief Abdel Fattah al-Burhan and Mohamed Hamdan Daglo, commander of the rival paramilitary Rapid Support Forces. The fighting has killed tens of thousands. "In Sudan, unrelenting violence has led to widespread hunger, disease and suffering," said WHO chief Tedros Adhanom Ghebreyesus. "Cholera has swept across Sudan, with all states reporting outbreaks. Nearly 100,000 cases have been reported since July last year." Oral cholera vaccination campaigns had been conducted in several states, including the capital Khartoum, he told a press conference with the Geneva UN correspondents' association ACANU. "While we are seeing a declining trend in numbers, there are gaps in disease surveillance, and progress is fragile," he said. "Recent floods, affecting large parts of the country, are expected to worsen hunger and fuel more outbreaks of cholera, malaria, dengue and other diseases." Cholera is an acute intestinal infection that spreads through food and water contaminated with bacteria, often from faeces. It causes severe diarrhoea, vomiting and muscle cramps. Cholera can kill within hours when not attended to, though it can be treated with simple oral rehydration, and antibiotics for more severe cases. There has been a global increase in cholera cases, and their geographical spread, since 2021. Malnutrition As for hunger, Tedros said there were reports from El-Fasher, the besieged capital of North Darfur state, that people were eating animal feed to survive. Across the country, millions are going hungry and around 770,000 children under five years old are expected to suffer from severe acute malnutrition this year. "In the first six months of this year, nutrition centres supported by WHO have treated more than 17,000 severely malnourished children with medical complications. But many more are beyond reach," Tedros warned. The UN health agency's efforts were being held back by limited access and a lack of funding, he added, with the WHO having received less than a third of the money it has appealed for to provide urgent health assistance in Sudan. The WHO director-general said that as long as the violence continues in Sudan, "we can expect to see more hunger, more displacement and more disease".
